122
Participants
Start Date
April 20, 2016
Primary Completion Date
November 5, 2019
Study Completion Date
February 19, 2021
Spartalizumab
Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
Investigator choice of chemotherapy
Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
Novartis Investigative Site, Taipei
NYU Laura and Isaac Perlmutter Cancer Center Laura & Isaac Perlmutter Ctr, New York
Novartis Investigative Site, Bangkok
Virginia Cancer Specialists, Fairfax
Northwest Georgia Oncology Center NWGA Onc - Carrollton, Marietta
Novartis Investigative Site, Taoyuan District
Karmanos Cancer Institute, Detroit
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Tainan City
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Songkhla
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Singapore
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Nice
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Kowloon
Novartis Investigative Site, Tuenmen
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY